Published on 11 Apr 2022 on Benzinga
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are trading higher Monday after the company announced a peer-reviewed publication on positive in vitro data with its Bentrio drug-free nasal spray against the SARS-CoV-2 delta variant.
The International Journal of Molecular Sciences published the peer-reviewed paper confirming Altamira's positive research findings.